Article Text

PDF
Childhood immunisation: what is the future?
  1. Andrew J Pollard
  1. Correspondence to:
    Dr Andrew J Pollard
    Department of Paediatrics, University of Oxford, Level 2, Children’s Hospital, Oxford OX3 9DU, UK; andrew.pollard{at}paediatrics.ox.ac.uk

Abstract

Improved immunisation programmes and the development of new vaccines provide unprecedented opportunities to improve and sustain the health of our children. There are major challenges ahead in communicating the benefits of immunisation to all populations and in delivering vaccines to those in greatest need. In this review on immunisation, I have asked international opinion leaders to comment on the present and the future of immunisation to provide signposts for the narrative.

  • DTP, diphtheria, tetanus, pertussis
  • Hib, Haemophilus influenzae type b
  • HPV, human papilloma virus
  • MenC, meningococcal serogroup C
  • WHO, World Health Organization

Statistics from Altmetric.com

Footnotes

  • AJP acts as chief investigator for clinical trials conducted on behalf of Oxford University sponsored by vaccine manufacturers (Sanofi-Pasteur MSD, Novartis Vaccines, GlaxoSmithKline Biologicals, Sanofi-Pasteur and Wyeth Vaccines), and has received assistance from manufacturers to attend scientific meetings. Industry-sourced consultancies and honoraria for lecturing or writing are paid directly to an independent charity or an educational fund held by the Department of Paediatrics, University of Oxford. AJP is also an inventor on a patent application in the area of MenB vaccines, and a Jenner Institute investigator.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Précis
    BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health